Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


19thAsia Pacific Diabetes Conference

Melbourne, Australia

Md. Faruque Pathan

Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Bangladesh

Title: Real-life effectiveness and tolerability of initial combination therapy with vildagliptin/metformin in drug-naïve patients with T2DM (Initial): A 24-week study from asia


Biography: Md. Faruque Pathan


Background: Type 2 diabetes mellitus (T2DM) prevalence in South-East Asia region is on the rise and there is currently limited evidence assessing early therapeutic interventions.1 We assessed the effectiveness and safety of Initial combiNation therapy with vildagliptin/metformin In drug naïve T2DM patients In a reAl Life (INITIAL) study.

Methods: INITIAL was a 24-week non-interventional, prospective study in drug-naïve T2DM patients across Asia (Bangladesh, India, Philippines, South Korea) with documented HbA1c >7.5% (>8.0% in India), who were prescribed vildagliptin/metformin initial combination within 4 weeks of study entry according to local label.2 The primary endpoint was change in HbA1c (DHbA1c) from baseline to week 24. Key secondary endpoints were achievement of HbA1c ≤7.0% and DHbA1c by baseline subgroups (varying HbA1c category and dosage).

Results: Out of 532 enrolled patients, 457 (85.9%) completed the study. Overall, study population was relatively young with mean age 49.6±11.27 years, mean HbA1c: 9.3±1.57%, diabetes duration: 0.8±2.47 years, BMI: 26.7±4.50 kg/m2. At baseline, approximately 30% patients had hypertension, dyslipidemia or diabetes family history, and 17.9% were obese. Most patients (70.6%) received twice daily vildagliptin/metformin (mostly 50/500 mg in 53.5%) with minimal dose changes. Overall, DHbA1c from baseline was statistically significant (p<0.001) both at week 12 (−1.6±1.59%), and 24 (−1.9±1.70%), and meaningful across baseline HbA1c categories and drug dosages (Table 1). Overall, 39.6% patients achieved HbA1c ≤7.0% and mean change in body weight was −1.1±2.62 kg. 48 (9.0%) AEs including 1 (0.2%) hypoglycemic episode were reported, with no SAEs or deaths.

Conclusion: Overall, in these relatively young drug-naïve T2DM Asian patients with high baseline HbA1c and often associated with CV risk factors vildagliptin/metformin combination was associated with significant and clinically relevant HbA1c reduction from baseline. This effect was seen early at week 12, was maintained over 24 weeks and was accompanied with good glycemic control and tolerability.